Answers are grounded in this paper and cite their sources.
Reactive oxygen species (ROS)-regulating biomaterials have been developed for diverse diseases. Their therapeutic value depends on the ROS species affected and the magnitude, direction, timing and location of redox intervention while preserving physiological signaling. Local pH deviations occur across diverse ROS-related pathological conditions and can influence biochemical processes that shape redox balance. Therefore, pathological pH is not merely a trigger for material activation, but a biologically relevant cue for coupling ROS regulation to local disease conditions. This review first delineates the origins and patterns of pH dysregulation in tumors, inflammatory lesions, infections and injured tissues. The effects of pathological pH on ROS generation, conversion and clearance, together with redox-mediated feedback on pH homeostasis, are then discussed. On this basis, it analyzes pH-responsive biomaterials in which pH governs cargo release, activation of ROS-regulating agents, or intrinsic catalytic activity. These biomaterials are classified by their pH-responsive components, including chemical bonds, biological molecules and nanozymes. Finally, it discusses translational barriers involving pH heterogeneity, unpredictable performance in biological environments, degradation-product safety, and manufacturing reproducibility. By linking pathological pH, redox biology and therapeutic design, this review provides principles to guide the development of pH-responsive biomaterials for ROS regulation in defined pathological contexts.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: